The sGC activator BAY 60-2770 has potent erectile activity in the rat

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 304, Issue 12, 2013, Pages

  Lasker, George F ^a   Pankey, Edward A ^a   Frink, Terrence J ^a   Zeitzer, Jonathan R ^a   Walter, Korey A ^a   Kadowitz, Philip J ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Erectile dysfunction; Impaired cavernosal nerve function; Oxidative stress

Indexed keywords

1H 1,2,4 OXADIAZOLO[4,3 A]QUINOXALIN 1 ONE; 3,3 BIS(2 AMINOETHYL) 1 HYDROXY 2 OXOTRIAZENE; BAY 60 2770; GUANYLATE CYCLASE ACTIVATOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; MALE; MEAN ARTERIAL PRESSURE; NERVE CRUSH; NERVE STIMULATION; NONHUMAN; PENIS ERECTION; PENIS INJURY; PRIORITY JOURNAL; RAT;

ERECTILE DYSFUNCTION; IMPAIRED CAVERNOSAL NERVE FUNCTION; OXIDATIVE STRESS;

ANIMALS; BENZOATES; BIPHENYL COMPOUNDS; BLOOD PRESSURE; ENZYME INHIBITORS; GUANYLATE CYCLASE; HYDRAZINES; HYDROCARBONS, FLUORINATED; INJECTIONS; MALE; NERVE CRUSH; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE; OXADIAZOLES; PENILE ERECTION; PENIS; PERIPHERAL NERVES; QUINOXALINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CYTOPLASMIC AND NUCLEAR;

EID: 84879165463     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00062.2013     Document Type: Article

References (29)

1. Agarwal A, Nandipati KC, Sharma RK, Zippe CD, Raina R. Role of oxidative stress in the pathophysiological mechanism of erectile dysfunction. J Androl 27: 335-347, 2006.
2. Andersson KE. Mechanisms of penile erection and basis for pharmaclogical treatment of erectile dysfunction. Pharmacol Rev 63: 811-859, 2011.
3. Andersson KE, Wagner G. Physiology of penile erection. Physiol Rev 75: 191-236, 1995.
4. Badejo AM Jr, Nossaman VE, Pankey EA, Bhartiya M, Kannadka, CB, Murthy SN, Nossaman BD, Kadowitz PJ. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase stimulator, BAY 41-8543, are modulated by nitric oxide. Am J Physiol Heart Circ Physiol 299: H1153-H1159, 2010.
5. Bivalacqua TJ, Sussan TE, Gebska MA, Strong TD, Berkowitz DE, Biswal S, Burnett AL, Champion HC. Sildenafil inhibits superoxide formation and prevents endothelial dysfunction in a mouse model of secondhand smoke induced erectile dysfunction. J Urol 181: 899-906, 2009.
6. Burnett AL, Lowenstein CJ, Bredt DS, Chang TS, Snyder SH. Nitric oxide: a physiologic mediator of penile erection. Science 257: 401-403, 1992.
7. Chen H, Levine YC, Golan DE, Michel T, Lin AJ. Atrial natriuretic peptide-initiated cGMP pathways regulate vasodilator-stimulated phosphoprotein phosphorylation and angiogenesis in vascular endothelium. J Biol Chem 283: 4439-4447, 2008.
8. Evgenov OV, Pacher P, Schmidt PM, Hasko G, Schmidt HH, Stasch JP. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 5: 755-768, 2006.
9. Gebska MA, Stevenson BK, Hemnes AR, Bivalacqua TJ, Haile A, Hesketh GG, Murray CI, Zaiman AL, Halushka MK, Krongkaew N, Strong TD, Cooke CA, El-Haddad H, Tuder RM, Berkowitz DE, Champion HC. Phosphodiesterase-5A (PDE5A) is localized to the endo thelial caveolae and modulates NOS3 activity. Cardiovasc Res 90: 353-363, 2011.
10. Giraldi A, Wagner G. Effects of pinacidil upon penile erectile tissue, in vitro and in vivo. Pharmacol Toxicol 67: 235-238, 1990.
11. Gratzke C, Angulo J, Chitaley K, Dai YT, Kim NN, Paick JS, Simonsen U, Uckert S, Wespes E, Andersson KE, Lue TF, Stief CG. Anatomy, physiology, and pathophysiology of erectile dysfunction. J Sex Med 7: 445-475, 2010.
12. Gur S, Kadowitz PJ, Hellstrom WJ. Exploring the potential of NO-independent stimulators and activators of soluble guanylate cyclase for the medical treatment of erectile dysfunction. Curr Pharm Des 16: 1619-1633.
13. Hellstrom WJG, Wang R, Kadowitz PJ, Domer FR. Potassium channel agonists cause penile erection in cats. Int J Imp Res 4: 27-35, 1992.
14. Hidalgo-Tamola J, Chitaley K. Review type 2 diabetes mellitus and erectile dysfunction. J Sex Med 6: 916-926, 2009.
15. Lasker GF, Maley JH, Kadowitz PJ. A review of the pathophysiology and novel treatments for erectile dysfunction. Adv Pharmacol Sci 2010: 2010.
16. Lasker GF, Pankey EA, Allain AV, Dhaliwal JS, Stasch JP, Murthy SN, Kadowitz PJ. Analysis of erectile responses to BAY 41-8543 and muscarinic receptor stimulation in the rat. J Sex Med 10: 704-718, 2013.
17. Lasker GF, Pankey EA, Allain AV, Murthy SN, Stasch JP, Kadowitz PJ. The selective Rho-kinase inhibitor azaindole-1 has long-lasting erec-tile activity in the rat. Urology 81: 465.e7-e14, 2013.
18. Lin G, Hayashi N, Carrion R, Chang LJ, Lue TF, Lin CS. Improving erectile function by silencing phosphodiesterase-5. J Urol 174: 1142-1148, 2005.
19. Magee TR, Kovanecz I, Davila HH, Ferrini MG, Cantini L, Vernet D, Zuniga FI, Rajfer J, Gonzalez-Cadavid NF. Antisense and short hairpin RNA (shRNA) constructs targeting PIN (Protein Inhibitor of NOS) ameliorate aging-related erectile dysfunction in the rat. J Sex Med 4: 633-643, 2007.
20. Minkes RK, Kvamme P, Higuera TR, Nossaman BD, Kadowitz PJ. Analysis of pulmonary and systemic vascular responses to cromakalim, an activator of K ATP channels. Am J Physiol Heart Circ Physiol 260: H957-H966, 1991.
21. Moon DG, Byun HS, Kim JJ. A KATP-channel opener as a potential treatment modality for erectile dysfunction. BJU Int 83: 837-841, 1999.
22. Pankey EA, Bhartiya M, Badejo AM Jr, Haider U, Stasch JP, Murthy SN, Nossaman BD, Kadowitz PJ. Pulmonary and systemic vasodilator responses to the soluble guanylyl cyclase activator, BAY 60-2770, are not dependent on endogenous nitric oxide or reduced heme. Am J Physiol Heart Circ Physiol 300: H792-H802, 2011.
23. Schmidt HH, Schmidt PM, Stasch JP. NO-and haem-independent soluble guanylate cyclase activators. Handb Exp Pharmacol 309-339, 2009.
24. Schmidt P, Schramm M, Schroder H, Stasch JP. Receptor binding assay for nitric oxide-and heme-independent activators of soluble guanylate cyclase. Anal Biochem 314: 162-165, 2003.
25. Shamloul R. The potential role of the heme oxygenase/carbon monoxide system in male sexual dysfunctions. J Sex Med 6: 324-333, 2009.
26. Stasch JP, Dembowsky K, Perzborn E, Stahl E, Schramm M. Cardio-vascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 135: 344-355, 2002.
27. Stasch JP, Pacher P, Evgenov OV. Soluble guanylate cyclase as an emerging therapeutic target in cardiopulmonary disease. Circulation 123: 2263-2273, 2011.
28. Stasch JP, Schmidt PM, Nedvetsky PI, Nedvetskaya TY, HSA, Meurer S, Deile M, Taye A, Knorr A, Lapp H, Muller H, Turgay Y, Rothkegel C, Tersteegen A, Kemp-Harper B, Muller-Esterl W, Schmidt HH. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 116: 2552-2561, 2006.
29. Zhao Y, Brandish PE, DiValentin M, Schelvis JP, Babcock GT, Marletta MA. Inhibition of soluble guanylate cyclase by ODQ. Biochemistry 39: 10848-10854, 2000.